Merck (MRK) FDA Approval of V114 Brings Blockbuster Potential - BofA Securities
Get Alerts MRK Hot Sheet
Rating Summary:
24 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham reiterated a Neutral rating and $80.00 price target on Merck (NYSE: MRK) after the company's pneumococcal conjugate vaccine Vaxneuvance (V114, a 15-valent PCV) received its first FDA approval for adults, in-line with the Sunday PDUFA date.
The analyst stated "The approval isn’t a surprise after the string of positive phase 3 data and Pfizer’s recent next-gen approval, with investors much more focused on how the commercial launch will shake out vs. Pfizer’s competing agent Prevnar20. We do think V114 has blockbuster potential (we model $1.35B peak sales vs. $1.1B cons), but given Pfizer’s already established dominant presence in the pneumococcal market and Prevnar20’s broader coverage (20-valent vs. 15-valent), we wouldn’t highlight V114 as a major growth driver for Merck."
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $78.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
- CIMC Enric Holdings Ltd. (3899:HK) (CIMEF) PT Lowered to HK$8.70 at HSBC
- Prysmian SpA (PRY:IM) (PRYMY) PT Raised to EUR53 at HSBC
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
PDUFA, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!